Abstract：
OBJECTIVE: Metronidazole (MTZ) is an antimicrobial agent used to treat anaerobic infections. It has been hypothesized that MTZ may also have anti-inflammatory properties, but the evidence is limited and has not been previously reviewed. Thus, this scoping review aimed to answer the following question: \"What is the evidence supporting anti-inflammatory properties of metronidazole that are not mediated by its antimicrobial effects?\"
METHODS: A scoping review was conducted according to the PRISMA-ScR statement. Five databases were searched up to January 2023 for studies evaluating the anti-inflammatory properties of MTZ used as monotherapy for treating infectious and inflammatory diseases.
RESULTS: A total of 719 records were identified, and 27 studies (21 in vivo and 6 in vitro) were included. The studies reported experimental evidence of MTZ anti-inflammatory effects on (1) innate immunity (barrier permeability, leukocyte adhesion, immune cell populations), (2) acquired immunity (lymphocyte proliferation, T-cell function, cytokine profile), and (3) wound healing/resolution of inflammation.
CONCLUSIONS: Taken together, this scoping review supported a potential anti-inflammatory effect of MTZ in periodontitis treatment. We recommend that future clinical studies should be conducted to evaluate specific MTZ anti-inflammatory pathways in the treatment of periodontitis.
METHODS: A scoping review was conducted according to the PRISMA-ScR statement. Five databases were searched up to January 2023 for studies evaluating the anti-inflammatory properties of MTZ used as monotherapy for treating infectious and inflammatory diseases.
RESULTS: A total of 719 records were identified, and 27 studies (21 in vivo and 6 in vitro) were included. The studies reported experimental evidence of MTZ anti-inflammatory effects on (1) innate immunity (barrier permeability, leukocyte adhesion, immune cell populations), (2) acquired immunity (lymphocyte proliferation, T-cell function, cytokine profile), and (3) wound healing/resolution of inflammation.
CONCLUSIONS: Taken together, this scoping review supported a potential anti-inflammatory effect of MTZ in periodontitis treatment. We recommend that future clinical studies should be conducted to evaluate specific MTZ anti-inflammatory pathways in the treatment of periodontitis.
摘要：
目的：甲硝唑（MTZ）是一种用于治疗厌氧菌感染的抗菌药物。有人假设MTZ也可能具有抗炎特性，但是证据有限，以前没有审查过。因此，本范围审查旨在回答以下问题：“有什么证据支持甲硝唑的抗炎特性，而不是由其抗菌作用介导？”
方法：根据PRISMA-ScR声明进行范围审查。截至2023年1月，搜索了五个数据库，用于评估MTZ用作治疗感染性和炎症性疾病的单一疗法的抗炎特性的研究。
结果：共确定了719条记录，共纳入27项研究(21项体内研究和6项体外研究)。研究报告了MTZ抗炎作用对(1)先天免疫(屏障通透性，白细胞粘附，免疫细胞群)，（2）获得性免疫（淋巴细胞增殖，T细胞功能,细胞因子谱)，和(3)伤口愈合/炎症消退。
结论：综合来看，这项范围综述支持MTZ在牙周炎治疗中的潜在抗炎作用.我们建议未来的临床研究应进行评估特定的MTZ抗炎途径治疗牙周炎。
方法：根据PRISMA-ScR声明进行范围审查。截至2023年1月，搜索了五个数据库，用于评估MTZ用作治疗感染性和炎症性疾病的单一疗法的抗炎特性的研究。
结果：共确定了719条记录，共纳入27项研究(21项体内研究和6项体外研究)。研究报告了MTZ抗炎作用对(1)先天免疫(屏障通透性，白细胞粘附，免疫细胞群)，（2）获得性免疫（淋巴细胞增殖，T细胞功能,细胞因子谱)，和(3)伤口愈合/炎症消退。
结论：综合来看，这项范围综述支持MTZ在牙周炎治疗中的潜在抗炎作用.我们建议未来的临床研究应进行评估特定的MTZ抗炎途径治疗牙周炎。
